Source: PR Newswire

Press Release: Sierra Oncology : Sierra Oncology to Report New Analyses Supporting Momelotinib's Anemia Benefits at ASH 2019

- New dynamic analyses of Phase 3 SIMPLIFY-1 transfusion data demonstrate that momelotinib patients are nearly 10-times more likely to remain transfusion free compared to ruxolitinib treated patients - VANCOUVER, Nov. 6, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Stephen Dilly's photo - President & CEO of Sierra

President & CEO

Stephen Dilly

CEO Approval Rating


Sierra is a clinical-stage drug development company that researches, develops and commercializes therapeutics for the treatment of cancer. Read more